This would centralise decision-making in a single and all-powerful statutory HTA body with powers over medicines, vaccines, blood products, diagnostics, medical devices and other technologies. …
The proposed centralisation of power needs careful consideration by other sectors
February 8, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News -
Australia risks losing more than jobs in its biopharmaceutical sector — it risks losing strategic capability
June 1, 2026 - - Latest News -
New PBS listings expand access to blood cancer therapies
June 1, 2026 - - Latest News -
Now you can see the next step in the process most are officially excluded from
June 1, 2026 - - Latest News -
Australia's HTA Review closed-loop process continues with 'Delphi' stage two
June 1, 2026 - - Latest News